SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Linda Kaplan who wrote (6487)5/7/1999 6:29:00 PM
From: BDR  Read Replies (1) of 7041
 
<<I still don't think that nausea, vomiting and diarrhea are conducive to a pleasant sexual experience. Silly me.>>

Hey, don't knock till you've tried it, I always say.(g)

<<I don't know why there would be better efficacy in an uncontrolled study than in a study that was controlled by placebo. Do you?>>

Patient selection could make the difference (were nitrate taking patients, i.e. sicker patients, excluded in both studies or just the one reporting better results) or the means of measuring success could be different. I thought most people studying impotence agreed to try to report results using a standardized measurement of outcomes so that one could make meaningful comparisons between studies. Can't tell since I don't have access to the details of the studies.

<<Certainly if initial dosage of Vasomax must be provided by a physician in office, that would be a deterrent to sales.>>

Vivus's MUSE is supposed to be administered the first time in the physician's office for the same reason. But that isn't the main deterent to sales of MUSE.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext